ArticleLupus science & medicine2023
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.
Article in Lupus science & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2026Guideline
- Targeting type I interferon in lupus panniculitis: a case-based systematic literature review.Rheumatology international · 2026Pooled it
- A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence.Frontiers in immunology · 2026Pooled it
- Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review.Dermatology and therapy · 2026Review
- Article
- Article
- Anifrolumab in Refractory Oral Manifestations in Systemic Lupus Erythematosus: A Case Report and Literature Review.Biologics : targets & therapy · 2026Article
- What's New in Cutaneous Lupus Erythematosus: Guidelines, Biologics, and Beyond.The Journal of clinical and aesthetic dermatology · 2026Review
- Cutaneous systemic lupus erythematosus in a woman with skin of colour.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Article
- Adjunctive anifrolumab for recalcitrant discoid lupus erythematosus in the setting of systemic lupus erythematosus: A case report.JAAD case reports · 2025Article
- Can Dermoscopy Be a Useful Follow-Up Tool in Patients with Discoid Lupus Treated with Anifrolumab?Diagnostics (Basel, Switzerland) · 2025Article
- Opportunities and limitations of B cell depletion approaches in SLE.Nature reviews. Rheumatology · 2025Review
- Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0).Biologics : targets & therapy · 2025Article
- Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report.SAGE open medical case reports · 2025Article
- Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus.JAAD case reports · 2025Article
- Treatment of recalcitrant discoid lupus erythematosus with roflumilast 0.3% cream following suboptimal response to anifrolumab and improvement of hypopigmentation.JAAD case reports · 2024Article
- Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments.American journal of clinical dermatology · 2024Review
- An update on clinical trials for cutaneous lupus erythematosus.The Journal of dermatology · 2024Review
- Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab.Mediterranean journal of rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific mucocutaneous manifestations in patients with systemic lupus erythematosus (SLE).
methodsA case series comprising four SLE patients with refractory CLE received anifrolumab (300mg) as add-on therapy. Medical history, serological markers and images were collected. Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) was assessed at baseline and post-treatment visits.
results
conclusionAnifrolumab demonstrates efficacy in treating refractory CLE subtypes and lupus non-specific mucocutaneous manifestations in SLE patients. Further studies are needed to establish response rates, optimal dosing, and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.